SPARC and neoplasm: The most enriched glycoproteins in tumour ECM compared to non-tumour ECM included thrombospondin-2 (16.9-fold), MXRA5 (14.4-fold), peroxidasin (2.5-fold), thrombospondin-1 (2.5-fold), SPARC (2.3-fold), FRAS1 (2.3-fold) and tenascin-C (2.1-fold) (Supplementary Figure 2; Supplementary Data 3).